Day: April 22, 2021

IRVINE, Calif., April 22, 2021 (GLOBE NEWSWIRE) — Viant Technology Inc. (NASDAQ: DSP), a leading people-based advertising software company, today announced it will release its first quarter 2021 financial results after U.S. markets close on Thursday, May 13, 2021. Viant will host a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the business and financial performance. First Quarter 2021 Results and Conference Call Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.viantinc.com.      About ViantViant® is a leading people-based advertising software company that enables marketers and their agencies to centralize the planning, buying and measurement of their advertising...

TORONTO, April 22, 2021 (GLOBE NEWSWIRE) — Platinex Inc. (CSE: PTX) (Frankfurt: 9PX) (the “Company” or “Platinex“) is pleased to announce the appointment of Jamie Lavigne and Blaine Webster to the Company’s technical committee. Both individuals bring significant industry experience including work directly in the area at Cote Gold deposit and in the Shining Tree camp. Jamie Lavigne has over 30 years of experience in exploration, resource delineation, and mining and has played key roles in several successful gold exploration and development projects. Mr. Lavigne completed the first two mineral resource estimates for the Cote Lake Gold deposit for Trelawney Mining and Exploration Inc. Upon the acquisition of Trelawney in 2012, Mr. Lavigne complete two mineral resource updates for IAMGOLD Corporation. Mr. Lavigne...

Englewood Cliffs, NJ, April 22, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has unanimously voted to uplist to the NASDAQ. Eric Weisblum, CEO, stated “Silo Pharma is proud to announce that we intend to begin the application process to list on the NASDAQ exchange. Uplisting to The NASDAQ Capital Market is an important milestone at Silo Pharma as we continue to execute on our initiatives to build long term shareholder value. The prospective uplisting will increase our visibility in the marketplace as well as expand our institutional shareholder base.” The listing of the Company’s common shares on a national exchange is subject to exchange approval and the ability of the Company...

BOCA RATON, Fla., April 22, 2021 (GLOBE NEWSWIRE) — Xeriant, Inc. (OTC PINK: XERI), a new aerospace and advanced materials technology holding company, and its affiliate Xeriant Europe s.r.o announced today that Retacell, Movychem’s fire protection product, is in the process of being tested and evaluated for specific certification designations, and is being field tested by leading global manufacturers. This proven technology represents not only a breakthrough for aviation and other transportation applications, but for green construction and many other uses. “Shortly after announcing our joint venture with Movychem through Xeriant Europe, we received overwhelming interest from several industry leaders looking to enhance the fire protection properties of various building materials. In fact, as part of the initial testing phase for...

Not for distribution to U.S. newswire services or for dissemination in the United States TORONTO, April 22, 2021 (GLOBE NEWSWIRE) — Giyani Metals Corp. (TSXV:EMM, GR:A2DUU8) (“Giyani” or the “Company”) is pleased to announce the appointment Red Cloud Financial Services (“Red Cloud”) to provide the Company with range of capital markets advisory and corporate communication services. The Company will also enter into a memorandum of understanding (“MOU”) with the Postgraduate Research in Iron and Manganese Ore Resource (PRIMOR) unit at Rhodes University in South Africa to award a bursary valued at $12,500 per year over the next two years. Red Cloud Appointment Under the engagement, Red Cloud will be paid a fee of $10,000 per month for services commencing May 1, 2021 and for an initial six-month period and the arrangement can automatically...

LGS is one of the most challenging developmental and epileptic encephalopathies to manage because of high seizure frequency and significant neurodevelopmental impairment. More LGS study patients treated with FINTEPLA (fenfluramine) showed improvement in each of the BRIEF 2 indexes that have been used to assess behavior, emotion, and cognitive function in intractable epilepsy and other developmental conditions. Improvement was statistically significant for Cognition (27% vs 13% placebo, p=0.046) and the Global Executive Composite score (25% vs 11% placebo, p=0.034), where approximately twice as many patients achieved clinically meaningful improvement.EMERYVILLE, Calif., April 22, 2021 (GLOBE NEWSWIRE) — Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced new data showing...

WINNIPEG, Manitoba, April 22, 2021 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF) NFI Group Inc. (“NFI” or the “Company”), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, today announced that its electric vehicles (“EVs”) have collectively travelled more than 40 million zero-emission miles. Through this milestone, NFI EVs have prevented nearly 150,000 imperial tons of greenhouse gas (“GHG”) emissions from entering the environment – the equivalent of removing 23,000 cars from the road for one year. In addition, NFI announced that New Flyer Infrastructure Solutions™, NFI’s full-suite infrastructure project management service, has now installed more than 200 EV chargers . “Today’s achievements are tomorrow’s gains. In reaching 40 million electric miles across NFI’s EV line up, we continue...

OTTAWA, April 22, 2021 (GLOBE NEWSWIRE) — Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (TSXV-CGP) (F-GWN1) (B-GWN1) (OTC-CTNXF) is pleased to provide an update on its Bramaderos gold and copper joint venture in southern Ecuador (see Figures 1 and 2) in which it has a 12.5% interest carried by JV partner and project operator Sunstone Metals Inc. (ASX: STM) through to the start of commercial production (see “About Bramaderos”, below). Figures related to this news release can be seen in PDF format by accessing the version of this release on the Company’s website (www.cornerstoneresources.com) or by clicking on the link below: https://cornerstoneresources.com/site/assets/files/5809/nr21-09figures.pdf. HIGHLIGHTS:Assays received from the upper 576m of hole BMDD008 that has intersected a broad gold-copper mineralized...

SINGAPORE, April 22, 2021 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on its clinical development activities. Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: “ASLAN made significant progress in the fourth quarter of 2020 and that momentum has carried over into 2021. After completing recruitment of the third cohort in our multiple ascending dose trial for ASLAN004 in the fourth quarter, we announced positive interim data supportive of its potential as a novel, first-in-class antibody targeting IL-13R with a differentiated efficacy and safety profile in...